Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrine Pharma (PPHM) Cotara for Treatment of Brain Cancer
Up)
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme, the deadliest form of brain cancer. The data from an ongoing Phase II study of Cotara in patients with recurrent GBM is being presented today at the XIV World Congress of Neurological Surgery Annual Meeting by Dr. Deepak Gupta, assistant professor of neurosurgery at the All India Institute of Medical Sciences (AIIMS) in New Delhi on behalf of the Cotara study team that includes Drs. A.K. Mahapatra, Ashish Suri and C.S. Bal.
Dr. Gupta will present interim data for 10 recurrent GBM patients at first relapse treated at AIIMS as part of an ongoing 40 patient Phase II clinical trial.
Dr. Gupta will present interim data for 10 recurrent GBM patients at first relapse treated at AIIMS as part of an ongoing 40 patient Phase II clinical trial.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- Chelsea Therapeutics (CHTP) Completes End-of-Review Meeting with FDA Over Northera NDA
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
